Answers are grounded in this paper and cite their sources.
Adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).
No takes yet. Share an insight, caveat, or question.
Tsuboi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: